References
- Torchilin VP . Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J.9 (2), 128 – 47 (2007).
- Deshpande PP Biswas S Torchilin VP . Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond.)8 (9), 1509 – 28 (2013).
- Milla P Dosio F Cattel L . PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr. Drug Metab.13 (1), 105 – 19 (2012).
- Maeda H . The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul.41, 189 – 207 (2001).
- Newman MS Colbern GT Working PK Engbers C Amantea MA . Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother. Pharmacol.43 (1), 1 – 7 (1999).
- Zalba S Garrido MJ . Liposomes, a promising strategy for clinical application of platinum derivatives. Expert Opin. Drug Deliv.10 (6), 829 – 44 (2013).
- Allen TM . Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer2 (10), 750 – 63 (2002).
- Toporkiewicz M Meissner J Matusewicz L Czogalla A Sikorski AF . Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges. Int. J. Nanomedicine10, 1399 – 414 (2015).
- Higashiyama S Iwabuki H Morimoto C Hieda M Inoue H Matsushita N . Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci.99 (2), 214 – 20 (2008).
- Yewale C Baradia D Vhora I Patil S Misra A . Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials34 (34), 8690 – 707 (2013).
- Martinelli E De Palma R Orditura M De Vita F Ciardiello F . Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin. Exp. Immunol.158 (1), 1 – 9 (2009).
- Mahipal A Kothari N Gupta S . Epidermal growth factor receptor inhibitors: coming of age. Cancer Control21 (1), 74 – 9 (2014).
- van der Meel R Vehmeijer LJ Kok RJ Storm G van Gaal EV . Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv. Drug Deliv. Rev.65 (10), 1284 – 98 (2013).
- Zalba S Contreras AM Haeri A et al. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. J. Control. Release210, 26 – 38 (2015).
- Yuan Q Lee E Yeudall WA Yang H . Dendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug delivery. Oral Oncol.46 (9), 698 – 704 (2010).
- Bhirde AA Patel V Gavard J et al. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano3 (2), 307 – 16 (2009).
- Yin Z Liu N Ma M Wang L Hao Y Zhang X . A novel EGFR-targeted gene delivery system based on complexes self-assembled by EGF, DNA, and activated PAMAM dendrimers. Int. J. Nanomedicine7, 4625 – 35 (2012).
- Shimada T Ueda M Jinno H et al. Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles. Anticancer Res.29 (4), 1009 – 14 (2009).
- Seshacharyulu P Ponnusamy MP Haridas D Jain M Ganti AK Batra SK . Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets16 (1), 15 – 31 (2012).
- Bunuales M Duzgunes N Zalba S Garrido MJ de Ilarduya CT . Efficient gene delivery by EGF-lipoplexes in vitro and in vivo. Nanomedicine (Lond.)6 (1), 89 – 98 (2011).
- Zalba S Navarro I Trocóniz IF Tros de Ilarduya C Garrido MJ . Application of different methods to formulate PEG-liposomes of oxaliplatin: evaluation in vitro and in vivo. Eur. J. Pharm. Biopharm.81 (2), 273 – 80 (2012).
- Song S Liu D Peng J et al. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int. J. Pharm.363 (1–2), 155 – 61 (2008).
- Beuttler J Rothdiener M Muller D Frejd FY Kontermann RE . Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL). Bioconjug. Chem.20 (6), 1201 – 8 (2009).
- Rouser G Fkeischer S Yamamoto A . Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids5 (5), 494 – 6 (1970).
- Lee PC Fonge H Hoang B Reilly RM Allen C . Targeting colorectal cancer cells with single-walled carbon nanotubes conjugated to anticancer agent SN-38 and EGFR antibody. Biomaterials34 (34), 8756 – 65 (2013).
- Skvortsov S Sarg B Lindner H et al. Cetuximab inhibits thymidylate synthase in colorectal cells expressing epidermal growth factor receptor. Proteomics Clin. Appl.2 (6), 908 – 14 (2008).
- Wild R Fager K Flefleh C et al. Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol. Cancer Ther.5 (1), 104 – 13 (2006).
- Shimizu M Deguchi A Lim JT Moriwaki H Kopelovich L Weinstein IB . (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin. Cancer Res.11 (7), 2735 – 46 (2005).
- Czekanska EM . Assessment of cell proliferation with resazurin-based fluorescent dye. Methods Mol. Biol.740, 27 – 32 (2011).
- Hansen CB Kao GY Moase EH Zalipsky S Allen TM . Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta1239 (2), 133 – 44 (1995).
- Kalimutho M Minutolo A Grelli S et al. Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance. Cancer Chemother. Pharmacol.67 (6), 1299 – 312 (2011).
- Mamot C Ritschard R Wicki A et al. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. J. Drug Target20 (5), 422 – 32 (2012).
- Carver RS Stevenson MC Scheving LA Russell WE . Diverse expression of ErbB receptor proteins during rat liver development and regeneration. Gastroenterology123 (6), 2017 – 27 (2002).
- Natarajan A Wagner B Sibilia M . The EGF receptor is required for efficient liver regeneration. Proc. Natl Acad. Sci. USA104 (43), 17081 – 6 (2007).
- Prantner AM Scholler N . Biological barriers and current strategies for modifying nanoparticle bioavailability. J. Nanosci. Nanotechnol.14 (1), 115 – 25 (2014).
- Weng KC Noble CO Papahadjopoulos-Sternberg B et al. Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett.8 (9), 2851 – 7 (2008).
- Lee H Fonge H Hoang B Reilly RM Allen C . The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol. Pharm.7 (4), 1195 – 208 (2010).